McAdam LLC Sells 2,725 Shares of Gilead Sciences, Inc. $GILD

Key Points

• McAdam LLC reduced its stake in Gilead Sciences, Inc. by 10.3% after selling 2,725 shares, bringing its total holdings to 23,628 shares valued at approximately $2.62 million.
• Gilead Sciences received multiple upgrades from analysts, with JPMorgan raising its price target from $135 to $145 and maintaining an "overweight" rating.
• The company announced a quarterly dividend of $0.79 per share, representing a 2.8% yield and a payout ratio of 62.95%.

McAdam LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,628 shares of the biopharmaceutical company's stock after selling 2,725 shares during the period. McAdam LLC's holdings in Gilead Sciences were worth $2,620,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the first quarter valued at approximately $25,000. Activest Wealth Management boosted its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the first quarter worth $29,000. Colonial Trust Advisors grew its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital raised its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research analyst reports. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Finally, UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $117.17.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock valued at $9,390,030. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $113.67 on Thursday. The stock's 50 day moving average price is $114.29 and its two-hundred day moving average price is $110.01. Gilead Sciences, Inc. has a 12-month low of $81.83 and a 12-month high of $121.83. The firm has a market capitalization of $141.04 billion, a price-to-earnings ratio of 22.64, a P/E/G ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.